NEW YORK, December 24, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting AbbVie Inc. (NYSE: ABBV), Baxter International Inc. (NYSE: BAX), IDEXX Laboratories Inc. (NASDAQ: IDXX), Kythera Biopharmaceuticals Inc. (NASDAQ: KYTH), and Medical Properties Trust, Inc. (NYSE: MPW). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
AbbVie Inc. Research Report
On December 19, 2013, AbbVie Inc.'s (AbbVie) stock declined 3.11%, ending the day's session at $52.63. Over the previous three trading sessions, shares of AbbVie declined 1.39%, compared to the S&P 500 which gained 1.29% during the same period. The Full Research Report on AbbVie Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Baxter International Inc. Research Report
On December 19, 2013, Baxter International Inc. (Baxter) announced that the US Food and Drug Administration (FDA) has granted approval to Baxter's FEIBA (Anti-Inhibitor Coagulant Complex) for Prophylactic Treatment of Hemophilia A&B Patients with Inhibitors. According to the Company, FEIBA is the first and only FDA-approved treatment for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A or B who have developed inhibitors. The Company informed that the approval is based on data from a pivotal Phase III study, known as FEIBA PROOF, in which treatment with a FEIBA prophylactic regimen showed a 72% reduction in median annual bleed rate (ABR) compared to treatment with an on-demand regimen. Baxter added that in the intent-to-treat (ITT) analysis, three of the 17 (18%) adult patients in the prophylactic arm reported no bleeding episodes. Ludwig Hantson, Ph.D., President of Baxter's BioScience business, said, "FEIBA has been an effective treatment for hemophilia patients with inhibitors for more than 35 years as an on-demand treatment. FEIBA was first licensed in the US as FEIBA VH and then as FEIBA NF. This additional indication for prophylactic treatment is aimed at reducing the number of bleeds among this patient population. This latest approval reflects our legacy of offering new approaches to help reduce the disease burden of hemophilia, and supports Baxter's ongoing commitment to pursuing a bleed-free world." The Full Research Report on Baxter International Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
IDEXX Laboratories Inc. Research Report
On December 19, 2013, IDEXX Laboratories Inc.'s (IDEXX) stock declined 0.18%, ending the day's session at $103.81. Over the previous three trading sessions, shares of IDEXX gained 0.37%, compared to the Nasdaq Composite which gained 0.71% during the same period. The Full Research Report on IDEXX Laboratories Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Kythera Biopharmaceuticals Inc. Research Report
On December 19, 2013, Kythera Biopharmaceuticals Inc.'s (Kythera Biopharmaceuticals) stock declined 0.96%, ending the day' session at $39.36. Over the previous three trading sessions, shares of Kythera gained 0.10% compared to the Nasdaq Composite which gained 0.71% during the same period. The Full Research Report on Kythera Biopharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Medical Properties Trust, Inc. Research Report
On December 3, 2013, Medical Properties Trust, Inc. (Medical Properties Trust) announced that the Company has completed the previously announced acquisition of the real estate of 11 rehabilitation facilities in Germany, operated by RHM Klinik-und Altenheimbetriebe GmbH & Co. KG (RHM). Medical Properties Trust reported that it financed the acquisition with the proceeds of the €200 million senior notes 2020, which were priced with a 5.75% coupon in October 2013. The Full Research Report on Medical Properties Trust, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner